Alzheimer's Disease
|
0.700 |
Biomarker
|
disease |
BEFREE |
A pan-cortical brain region co-expression network analysis identified pathways and genes (eg, glycogen synthase kinase 3β) that were significantly associated with clinical characteristics of AD (such as neurofibrillary score) in males only.
|
30394676 |
2019 |
Alzheimer's Disease
|
0.700 |
Biomarker
|
disease |
BEFREE |
Following a multitarget approach, in this paper a series of polycyclic maleimide-based derivatives were designed and synthesized aimed at simultaneously modulate neuronal calcium channels and glycogen synthase kinase 3-beta (GSK-3β), validated targets to combat Alzheimer' disease.
|
30530190 |
2019 |
Alzheimer's Disease
|
0.700 |
Biomarker
|
disease |
BEFREE |
Glycogen synthase kinase-3β (GSK-3β) represents a relevant drug target for the treatment of neurodegenerative pathologies including Alzheimer's disease.
|
31242571 |
2019 |
Alzheimer's Disease
|
0.700 |
AlteredExpression
|
disease |
BEFREE |
Evidence indicates that Schisandrin inhibition of Aβ<sub>1-42</sub> -mediated cellular damage in AD neurons may involve activation of the PI3K/Akt signaling pathway where up-regulation of <i>p</i>-Akt activity consequently leads downstream to decreased activity of <i>p</i>-GSK-3β phosphorylation accompanied by reduced tau protein.
|
31739764 |
2019 |
Alzheimer's Disease
|
0.700 |
Biomarker
|
disease |
BEFREE |
Glycogen synthase kinase 3β (GSK3β) is a key component of pathogenesis in Alzheimer's disease, and its inhibitors can restore cognitive function as therapeutic interventions in neurodegenerative diseases.
|
31561361 |
2019 |
Alzheimer's Disease
|
0.700 |
Biomarker
|
disease |
BEFREE |
It is concluded that the analogues to GSK-3β inhibitors were optimized in relation to the toxicity of template, being presented as promising drug candidates for Alzheimer's disease treatment.
|
31749432 |
2019 |
Alzheimer's Disease
|
0.700 |
Biomarker
|
disease |
BEFREE |
The new inhibitors are valuable chemical probes and drug leads with therapeutic potential to tackle AD and other GSK-3β relevant diseases.
|
29381861 |
2018 |
Alzheimer's Disease
|
0.700 |
Biomarker
|
disease |
BEFREE |
For this reason, other biochemical pathways associated with the pathophysiology of AD have been explored as alternatives to the treatment of this condition such as inhibition of β-secretase and glycogen synthase kinase-3β.
|
30191777 |
2018 |
Alzheimer's Disease
|
0.700 |
Biomarker
|
disease |
BEFREE |
In AD, GSK-3β plays an important role in hyperphosphorylation of microtubule-associated protein tau (tau), which is one of the pathological features in AD.
|
29158110 |
2018 |
Alzheimer's Disease
|
0.700 |
Therapeutic
|
disease |
RGD |
Vildagliptin prevents cognitive deficits and neuronal apoptosis in a rat model of Alzheimer's disease.
|
29257340 |
2018 |
Alzheimer's Disease
|
0.700 |
Biomarker
|
disease |
BEFREE |
Tau-Centric Multitarget Approach for Alzheimer's Disease: Development of First-in-Class Dual Glycogen Synthase Kinase 3β and Tau-Aggregation Inhibitors.
|
30078314 |
2018 |
Alzheimer's Disease
|
0.700 |
GeneticVariation
|
disease |
GWASCAT |
Genome-wide association study of Alzheimer's disease endophenotypes at prediagnosis stages.
|
29274321 |
2018 |
Alzheimer's Disease
|
0.700 |
Biomarker
|
disease |
BEFREE |
Glycogen synthase kinase 3β (GSK3β) is a highly conserved serine/threonine kinase that has been implicated in both psychiatric and neurodegenerative diseases including schizophrenia, bipolar disorder, and Alzheimer's disease; therefore regulating its activity has become an important strategy for treatment of cognitive impairments in these disorders.
|
29449801 |
2018 |
Alzheimer's Disease
|
0.700 |
Biomarker
|
disease |
BEFREE |
Caspase-3 and GSK-3β inhibitor ameliorated memory impairments and synaptic deficits in Aβ-injected AD model mice.
|
29079294 |
2018 |
Alzheimer's Disease
|
0.700 |
Biomarker
|
disease |
BEFREE |
Therefore, one of the mechanisms of action of KK against AD may be the inhibition of GSK-3β and one of the active components of KK is the root of <i>S. miltiorrhiza</i> and its constituents: rosmarinic acid, magnesium lithospermate B, and salvianolic acids A, B, and C. Our results demonstrate the pharmacological basis for the use of KK against AD.
|
30413117 |
2018 |
Alzheimer's Disease
|
0.700 |
AlteredExpression
|
disease |
BEFREE |
GLP-1 receptor agonists downregulate aberrant GnT-III expression in Alzheimer's disease models through the Akt/GSK-3β/β-catenin signaling.
|
29223528 |
2018 |
Alzheimer's Disease
|
0.700 |
AlteredExpression
|
disease |
BEFREE |
Melatonin significantly ameliorated the cognitive function and mitochondrial damage in AD mice, reduced the expression levels of GSK-3β, caspase-3, Aβ<sub>1-42</sub> , BACE1, p-tau protein and increased the expressions of PP2A and Bcl-2.
|
28994117 |
2018 |
Alzheimer's Disease
|
0.700 |
AlteredExpression
|
disease |
BEFREE |
Consistent with its critical roles in normal cells, abnormalities in GSK-3β activity have been implicated in diabetes, heart disease, Parkinson disease, and Alzheimer's disease.
|
29144001 |
2018 |
Alzheimer's Disease
|
0.700 |
Biomarker
|
disease |
BEFREE |
Previous studies in high-fat diet-induced AD animal models have shown that brain insulin resistance in these animals leads to the accumulation of amyloid beta (Aβ) and the reduction in GSK-3β phosphorylation, which promotes tau phosphorylation to cause AD.
|
27810390 |
2017 |
Alzheimer's Disease
|
0.700 |
Biomarker
|
disease |
BEFREE |
A physicochemical descriptor based method for effective and rapid screening of dual inhibitors against BACE-1 and GSK-3β as targets for Alzheimer's disease.
|
28950235 |
2017 |
Alzheimer's Disease
|
0.700 |
Biomarker
|
disease |
BEFREE |
Thus, our previous and present findings raise the unifying prospect that Aβ•CaSR signaling plays a crucial role in AD development and progression by simultaneously activating (i) the amyloidogenic processing of amyloid precursor holoprotein, whose upshot is a surplus production and secretion of Aβ<sub>42</sub> oligomers, and (ii) the GSK-3β-mediated increased production of p-Tau oligomers which are next released extracellularly inside exosomes.
|
28473749 |
2017 |
Alzheimer's Disease
|
0.700 |
Biomarker
|
disease |
BEFREE |
Dual BACE-1/GSK-3β Inhibitors to Combat Alzheimer's Disease: A Focused Review.
|
29332582 |
2017 |
Alzheimer's Disease
|
0.700 |
AlteredExpression
|
disease |
BEFREE |
Accumulative evidence demonstrates that GSK-3β inactivation may be potentially developed as the promising strategy in management of many diseases, such as Alzheimer's disease (AD) and Parkinson's disease (PD).
|
29190615 |
2017 |
Alzheimer's Disease
|
0.700 |
Biomarker
|
disease |
BEFREE |
7-bromoindirubin-3-oxime (7Bio), an indirubin derivative derived from indirubin-3-oxime, possesses inhibitory effects against cyclin-dependent kinase-5 (CDK5) and glycogen synthase kinase-3β (GSK3β), two pharmacological targets of Alzheimer's disease (AD).
|
29234273 |
2017 |
Alzheimer's Disease
|
0.700 |
Biomarker
|
disease |
BEFREE |
Our findings shed new light on the role of calpain-GSK-3β-PP2A in tau pathogenesis of AD.
|
28267204 |
2017 |